Cencora, Inc. $COR Shares Bought by Vontobel Holding Ltd.

Vontobel Holding Ltd. increased its position in shares of Cencora, Inc. (NYSE:COR) by 7,699.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 250,846 shares of the company’s stock after purchasing an additional 247,630 shares during the quarter. Vontobel Holding Ltd. owned approximately 0.13% of Cencora worth $75,317,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Mosley Wealth Management boosted its position in Cencora by 11.5% in the third quarter. Mosley Wealth Management now owns 407 shares of the company’s stock worth $122,000 after purchasing an additional 42 shares during the last quarter. TD Waterhouse Canada Inc. increased its position in shares of Cencora by 139.8% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 156,789 shares of the company’s stock valued at $47,076,000 after purchasing an additional 91,404 shares during the last quarter. KFG Wealth Management LLC increased its position in shares of Cencora by 14.7% during the 3rd quarter. KFG Wealth Management LLC now owns 2,054 shares of the company’s stock valued at $617,000 after purchasing an additional 263 shares during the last quarter. Hanson & Doremus Investment Management increased its position in shares of Cencora by 700.0% during the 3rd quarter. Hanson & Doremus Investment Management now owns 616 shares of the company’s stock valued at $185,000 after purchasing an additional 539 shares during the last quarter. Finally, Pension & Wealth Management Advisors Inc. bought a new stake in shares of Cencora during the 3rd quarter worth $99,000. 97.52% of the stock is owned by institutional investors.

Cencora Stock Performance

Shares of COR stock traded down $0.87 on Friday, hitting $340.54. 1,978,868 shares of the stock were exchanged, compared to its average volume of 1,282,490. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53. The firm has a market capitalization of $64.99 billion, a PE ratio of 25.30, a P/E/G ratio of 1.75 and a beta of 0.58. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The firm’s 50 day moving average is $320.38 and its two-hundred day moving average is $303.34.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.35 by $0.13. The business had revenue of $84.75 billion for the quarter, compared to analysts’ expectations of $84.31 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business posted $4.00 EPS. Sell-side analysts expect that Cencora, Inc. will post 17.87 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Friday, August 14th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is 17.83%.

Insider Activity

In related news, EVP Elizabeth Campbell sold 11,300 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the sale, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. This represents a 36.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.38% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on COR shares. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Robert W. Baird raised their price objective on shares of Cencora from $370.00 to $373.00 and gave the stock an “outperform” rating in a report on Monday, October 12th. UBS Group decreased their price objective on shares of Cencora from $430.00 to $400.00 and set a “buy” rating for the company in a report on Friday. Morgan Stanley lifted their price objective on shares of Cencora from $342.00 to $346.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Evercore reiterated an “outperform” rating and issued a $350.00 target price (up from $330.00) on shares of Cencora in a research note on Thursday, August 6th. Fourteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $363.81.

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.